Kyverna Therapeutics, Inc.
KYTX
$1.86
$0.031.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -81.40% | -- | -- | -139.55% | -143.26% |
| Total Depreciation and Amortization | 21.86% | -- | -- | 22.34% | 23.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -126.70% | -- | -- | 226.10% | 2.59% |
| Change in Net Operating Assets | -96.63% | -- | -- | -23.94% | 176.91% |
| Cash from Operations | -99.65% | -146.94% | -- | -122.77% | -110.54% |
| Capital Expenditure | -59.28% | -- | -- | -1,839.29% | -2,683.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.06% | -- | -- | -994.07% | 111.19% |
| Cash from Investing | -7.76% | 101.25% | -- | -999.88% | 109.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -12.79% | -- | -- | -37.50% | -51.03% |
| Issuance of Common Stock | -88.36% | -- | -- | 1,421,712.50% | 539.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | 85.01% | -100.44% | -- | 234,856.25% | -1,305.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -168.93% | 11.47% | -- | 9,137.46% | 87.60% |